.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Fuji
Federal Trade Commission
Moodys
Dow
Mallinckrodt
Teva
Farmers Insurance
McKinsey
Novartis

Generated: January 23, 2018

DrugPatentWatch Database Preview

US Patents With Foreign Priority to United Kingdom Patent: 9625458

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Novartis Pharms CorpTYKERBlapatinib ditosylateTABLET;ORAL022059-001Mar 13, 2007RXYesYes➤ Subscribe➤ SubscribeTREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
Novartis Pharms CorpTYKERBlapatinib ditosylateTABLET;ORAL022059-001Mar 13, 2007RXYesYes➤ Subscribe➤ SubscribeTREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
Novartis Pharms CorpTYKERBlapatinib ditosylateTABLET;ORAL022059-001Mar 13, 2007RXYesYes➤ Subscribe➤ SubscribeYYTREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR
Novartis Pharms CorpTYKERBlapatinib ditosylateTABLET;ORAL022059-001Mar 13, 2007RXYesYes➤ Subscribe➤ SubscribeYYTREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Table 'thinkbio_newdpw.patent_gazette' doesn't exist